TransEnterix Announces Southern Surgical Hospital to Initiate a Senhance® Digital Laparoscopic Program
December 17 2020 - 6:50AM
Business Wire
Represents the Third Senhance Surgical Program
Initiated in Louisiana
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that Southern Surgical Hospital has entered into an agreement to
lease and utilize a Senhance® Surgical System.
“We are pleased to support Southern Surgical Hospital in
advancing care with the addition of the Senhance Surgical System,”
said Anthony Fernando, President and Chief Executive Officer at
TransEnterix. “Hospitals throughout the world, and the US, remain
interested in advancing minimally invasive surgery with digital
assistance while managing health care costs and resources. This
Senhance digital laparoscopic program will be a good complement to
their outpatient minimally invasive surgical care initiatives for
their surgeons and patients.
Southern Surgical Hospital is located in Slidell, Louisiana and
provides in-patient and out-patient surgical procedures in the
southeast Louisiana area. Established 15 years ago, Southern
Surgical Hospital is a partnership with local physicians and has a
CMS 5-star rating along with a Becker’s “Top-rated hospital for
patient experience” in Louisiana distinction.
“We remain committed to utilizing advanced technology to offer
our patients the best possible surgical experience,” said Dr. James
Redmann, general and bariatric surgeon and Director of Bariatrics
at Southern Surgical Hospital. “Digital assistance in surgery is
exciting because it can enable surgeons with better vision,
precision, and augmented intelligence capabilities that ultimately
translate to a great surgical experience for our patients. Our
surgeons are looking forward to being a part of creating this
future with programs such as this one with Senhance.”
“Our team is excited to add new technologies to our already
excellent minimally invasive surgery program,” said Michael
Pisciotta, Chief Executive Officer of Southern Surgical Hospital.
“Our goal is to partner with innovative physicians to offer
patients the very best in outpatient, minimally invasive surgical
care. The addition of the Senhance System is part of our commitment
to utilize advanced technology to best serve our patients and
community.”
The Senhance System is the first new abdominal robotic surgery
platform to receive FDA clearance since 2000. It is the first and
only digital laparoscopic surgical platform designed to maintain
laparoscopic minimally invasive surgical standards while providing
digital benefits such as haptic feedback, robotic precision,
comfortable ergonomics, advanced instrumentation including 3 mm
microlaparoscopic instruments, eye-sensing camera control, and
reusable standard instruments to help maintain per-procedure costs
similar to traditional laparoscopy. TransEnterix recently launched
the first machine vision system in robotic surgery. This
first-of-its-kind augmented intelligence capability is powered by
the new Intelligent Surgical Unit™ on the Senhance Surgical
System.
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new Intelligent Surgical Unit™ (ISU™) that enables
augmented intelligence in surgery. The Senhance Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, and select other countries. For a
complete list of indications for use, please visit:
https://www.transenterix.com/indications-for-use/.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and Southern Surgical Hospital initiating a program with the
Senhance System. These statements and other statements regarding
our future plans and goals constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are
intended to qualify for the safe harbor from liability established
by the Private Securities Litigation Reform Act of 1995. Such
statements are subject to risks and uncertainties that are often
difficult to predict, are beyond our control and which may cause
results to differ materially from expectations and include whether
the Senhance System will be part of advancing care at Southern
Surgical Hospital, whether the Senhance System will be a good
compliment to Southern Surgical Hospital’s outpatient minimally
invasive surgical care initiatives for their surgeons and patients
and whether the Senhance System will enable surgeons with better
vision, precision and augmented intelligence capabilities that can
translate to a great surgical experience. For a discussion of the
risks and uncertainties associated with TransEnterix's business,
please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K for the
year ended December 31, 2019, filed with the SEC on March 16, 2020
and our other filings we make with the SEC. You are cautioned not
to place undue reliance on these forward looking statements, which
are based on our expectations as of the date of this press release
and speak only as of the origination date of this press release. We
undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201217005281/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Apr 2024 to May 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From May 2023 to May 2024